Journal
MOLECULAR CANCER RESEARCH
Volume 20, Issue 1, Pages 11-29Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-21-0038
Keywords
-
Categories
Funding
- La Ligue contre le Cancer
- Fondation ARC [PJA 22020060002212]
- Agence Nationale de la Recherche (PLASCAN) [ANR-17-CONV-0002]
- Institut National du Cancer (INCa) (PRT-K program) [2018-024 EMT-CoNCEPT]
- Integrated Cancer Research Site LYriCAN [INCa-DGOS-Inserm_12563]
- Agence Nationale de la Recherche (ANR) [ANR-17-CONV-0002] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
In patients with metastatic cancer, complete tumor response to systemic therapies is rare due to early molecular adaptation in cancer cells, resulting in residual lesions. Evidence suggests that drug-tolerant persister cells, characterized by reduced drug sensitivity and cell proliferation, play a role in maintaining residual disease and may contribute to resistant phenotypes.
In patients with cancer with metastatic disease, the rate of complete tumor response to systemic therapies is low, and residual lesions persist in the majority of patients due to early molecular adaptation in cancer cells. A growing body of evidence suggests that a subpopulation of drug-tolerant persister cells-a reversible phenotype characterized by reduced drug sensitivity and decreased cell proliferation-maintains residual disease and may serve as a reservoir for resistant phenotypes. The survival of these residual tumor cells can be caused by reactivation of specific signaling pathways, phenotypic plasticity
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available